View Older Stories View More Recent Stories

Nov 14, 2019 07:42AM Anavex Life Sciences (AVXL) Receives Rare Pediatric Disease Designation from FDA for ANAVEX 2-73 for Treatment of Rett Syndrome
Nov 14, 2019 07:00AM Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment of Rett Syndrome
Nov 6, 2019 07:00AM Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome
Oct 9, 2019 07:01AM Anavex Life Sciences (AVXL) Announces ATTENTION-AD ANAVEX 2-73 Extension Clinical Study in Early AD
Oct 9, 2019 07:00AM Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease
Oct 2, 2019 07:02AM Anavex Life Sciences (AVXL) Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for Treatment of AD
Oct 2, 2019 07:00AM Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’s Disease
Sep 27, 2019 05:48AM Anavex Life Sciences (AVXL) Highlights Preliminary Clinical Efficacy Data from U.S. Rett Syndrome Phase 2 ANAVEX2-73 Study
Sep 27, 2019 03:00AM Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study
Sep 26, 2019 07:00AM Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
Sep 18, 2019 07:00AM Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference
Sep 16, 2019 07:08AM Anavex Life Sciences (AVXL) Announces Prelim. Clinical Efficacy Data of U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome
Sep 16, 2019 07:00AM Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome
Sep 5, 2019 07:00AM Anavex Life Sciences to Present at the Janney Healthcare Conference 2019
Sep 4, 2019 07:10AM Anavex Life Sciences (AVXL) Begins EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Rett Syndrome
Sep 4, 2019 07:00AM Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Rett Syndrome
Aug 7, 2019 07:00AM Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates
Aug 2, 2019 07:00AM Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019
Jul 31, 2019 07:26AM Anavex Life Sciences (AVXL) Reports Data from Review by Independent DSMB for U.S. Phase 2 Clinical Trial of ANAVEX2-73
Jul 31, 2019 07:00AM Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome
Jul 29, 2019 07:11AM Anavex Life Sciences (AVXL) Receives Positive Opinion for Orphan Designation from EMA for ANAVEX2-73 for Treatment of Rett Syndrome
Jul 29, 2019 07:00AM Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett Syndrome
Jul 17, 2019 11:47AM Anavex Life Sciences (AVXL) Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Response in Patients Treated with ANAVEX2-73 at AAIC
Jul 17, 2019 11:45AM Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Response in Patients Treated with ANAVEX®2-73 at 2019 Alzheimer’s Association
Jun 25, 2019 07:03AM Anavex Life Sciences (AVXL) Reports First Patient Dosed in Extension Study to U.S. Phase 2 Clinical Trial of ANAVEX
Jun 25, 2019 07:00AM Anavex Life Sciences Announces First Patient Dosed in Extension Study to its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients for Rett Syndrome
Jun 6, 2019 07:06AM Anavex Life Sciences (AVXL) Reports First Patient Dosed in Phase 2 Clinical Trial of ANAVEX2-73 for the Treatment of Rett Syndrome (AVATAR)
Jun 6, 2019 07:00AM Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome (AVATAR)
May 8, 2019 08:00AM Rett Syndrome Association of Australia and Anavex Life Sciences Announce Initiation of the Phase 2 AVATAR Clinical Study in Patients with Rett Syndrome
May 8, 2019 07:00AM Anavex Life Sciences Reports Fiscal 2019 Second Quarter Financial Results and Provides Clinical Study Updates
May 6, 2019 07:00AM Anavex Life Sciences to Announce Fiscal 2019 Second Quarter Financial Results on Wednesday May 8th, 2019
Apr 5, 2019 04:01PM Anavex Life Sciences to Present at the H.C. Wainwright Annual Global Life Sciences Conference
Mar 28, 2019 07:11AM Anavex Life Sciences (AVXL) Highlights Data On ANAVEX2-73 in Alzheimer’s Disease at ASENT 2019 Annual Meeting
Mar 28, 2019 07:00AM Anavex Life Sciences Presents Data On ANAVEX®2-73 in Alzheimer’s Disease at the American Society for Experimental Neurotherapeutics - ASENT 2019 Annual Meeting
Mar 18, 2019 07:02AM Anavex Life Sciences (AVXL) Reports First Patient Dosed in Phase 2 Clinical Trial of ANAVEX2-73 for Treatment of Rett Syndrome in U.S.
Mar 18, 2019 07:00AM Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome in the U.S.
Mar 13, 2019 07:00AM Anavex Life Sciences to Present at the 31st Annual ROTH Conference 2019
Mar 11, 2019 07:16AM Anavex Life Sciences (AVXL) Announces 50% Patient Enrollment Threshold in ANAVEX2-73 Parkinson’s Disease Dementia (PDD) Phase 2 Study Ahead of Schedule
Mar 11, 2019 03:00AM Anavex Life Sciences Reaches 50% Enrollment Threshold in ANAVEX®2-73 Parkinson’s Disease Dementia (PDD) Phase 2 Study Ahead of Schedule
Mar 6, 2019 07:00AM Anavex Life Sciences to Present at the Cowen 39th Annual Health Care Conference 2019
Mar 4, 2019 07:00AM Anavex Life Sciences Reports Publication of New Data that Show ANAVEX®2-73 Induces Cellular Recycling Process Linked to the Prevention and Treatment of Age-Associated Diseases
Feb 7, 2019 07:00AM Anavex Life Sciences Reports Fiscal 2019 First Quarter Financial Results And Provides Clinical Study Updates
Feb 4, 2019 07:00AM Anavex Life Sciences to Present at the 2019 BIO CEO & Investor Conference
Jan 31, 2019 08:00AM Anavex Life Sciences to Announce Fiscal 2019 First Quarter Financial Results on Thursday, February 7th, 2019
Jan 2, 2019 07:00AM Anavex Life Sciences Announces the Appointment of Walter E Kaufmann, MD as Chief Medical Officer
Dec 12, 2018 07:00AM Anavex Life Sciences Reports Fiscal Year 2018 Financial Results And Provides Clinical Study Update
Dec 10, 2018 07:00AM Anavex Life Sciences to Announce 2018 Fiscal Year End Financial Results on Wednesday, December 12, 2018
Nov 8, 2018 07:00AM Anavex Life Sciences Strengthens its Scientific Advisory Board with Distinguished Researcher for Clinical Treatment of Parkinson’s Disease Dementia (PDD)
Oct 30, 2018 07:18AM Anavex Life Sciences (AVXL) Reports First Patient Enrolled in Phase 2 Clinical Trial of ANAVEX2-73 for Treatment of Parkinson’s Disease Dementia
Oct 30, 2018 07:00AM First Patient Enrolled in Anavex Life Sciences Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Disease Dementia (PDD)
View More Recent Stories View Older Stories